Janssen Signs Exclusive Worldwide Agreement with Arrowhead for $3.7B

 Janssen Signs Exclusive Worldwide Agreement with Arrowhead for $3.7B

Janssen (J&J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression


  • The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional treatments for Hepatitis B
  • Arrowhead to get an upfront $175M with $1.6B milestone payments for ARO-HBV. $1.9B in option and milestone payments for the three additional treatments of Hepatitis B. Janssen will invest $75M in its Arrowhead’s shares at a price of $23/share
  • Janssen will take on Arrowhead’s ARO-HBV drug candidate currently evaluated in P-I/II, will also initiate the P-IIb trial for ARO-HBV and up to three RNAi therapeutics. Janssen will also jointly develop RNAi therapeutics using Arrowhead’s Targeted RNAi Molecule (TRiM) platform. The transaction is expected to close in Q4’18

Click here to read full press release/ article | Ref: Janssen | Image: Janssen

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post